• It is interesting that Li et

  2024-02-21

  

  It is interesting that Li et al. (2008) reported that AChR-immunized FcγRIIB knock out (KO) mice are significantly resistant to antibody-mediated EAMG. This is in contrast with previous studies, but does not contradict the results presented here. Despite their observation that the incidence and seve

• During the year study period

  2024-02-21

  

  During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk BAY 61-3606 of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decreas

• The most potent compounds within

  2024-02-21

  

  The most potent compounds within the current series of compounds were therefore , , , , and , with colony stimulating factor 1 receptor possessing the best selectivity towards the lyase reaction in comparison to the hydroxylase reaction, indeed, this compound was found to possess an IC value of 1

• br Acknowledgements br Introduction Double stranded DNA brea

  2024-02-21

  

  Acknowledgements Introduction Double-stranded DNA breaks (DSBs) are among the most deleterious DNA lesions that threaten genomic integrity. DSBs are generated not only by exogenous DNA-damaging agents but also by normal cellular processes such as V(D)J recombination, meiosis, and DNA replicati

• The putative residue apelin proprotein

  2024-02-21

  

  The putative 55-residue apelin proprotein (proapelin or apelin-55) is processed from a 77-residue preproprotein through removal of a 22-residue signal peptide (Table 1). Apelin-55 is further processed into bioactive isoforms of 36, 17, or 13 residues, likely through protease-mediated mechanisms. To

• what you have Luo Dehm Raj Luo Attard Balk Bevan

  2024-02-20

  

  Luo, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong, Gao, Gleave, Heemers, Kanayama, Kittler, Lang, Lee, Logothetis, Matusik, Plymate, Sawyers, Selth, Soule, Tilley, Weigel, Zoubeidi, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong,

• Secondly as pointed out by Sulentic and Kaminski

  2024-02-20

  

  Secondly, as pointed out by Sulentic and Kaminski in their recent paper [90], most of the AhR literature to date has focused on mouse AhR. Although both mouse and human AhR are interchangeable in many in vitro systems, the in vivo ligand binding affinity is drastically different between the two AhRs

• br AHR mediates TCDD toxicity

  2024-02-20

  

  AHR mediates TCDD toxicity and wasting syndrome TCDD causes numerous toxicities in laboratory animals, including teratogenesis, hepatic steatosis, thymic atrophy, immune dysfunction and a lethal wasting syndrome [17]. The dose-dependent sensitivity to TCDD-induced toxicities varies widely among l

• br Mechanisms for regulation of intracellular cholesterol ho

  2024-02-20

  

  Mechanisms for regulation of intracellular cholesterol homeostasis Cells maintain intracellular free cholesterol levels and distribution within stringent tolerances by several mechanisms [55]: (1) uptake of native LDL (the major extracellular carrier of cholesterol) by LDL receptors and modified

• PD173955 The disease stimulatory effects of hyperadiponectin

  2024-02-20

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• br Conflicts of interest br Newly Identified Mechanisms of

  2024-02-20

  

  Conflicts of interest Newly Identified Mechanisms of APN Resistance Hold Therapeutic Potential APN, APN Receptors, and APN Cardiovascular Protection APN Resistance in Cardiovascular Disease The Molecular Mechanisms of APN Resistance Concluding Remarks and Future Directions Finally,

• Several tertiary prevention studies are currently underway e

  2024-02-20

  

  Several tertiary prevention studies are currently underway examining the use of dutasteride for prostate cancer treatment: (1) during expectant management of prostate cancer, (2) after radical prostatectomy in men at high risk for relapse, and (3) in men with metastatic disease. The Reduction by Dut

• In an effort to determine if one ARI was

  2024-02-20

  

  In an effort to determine if one 5ARI was more effective than the other, the Enlarged Prostate International Comparator Study (EPICS) [17] compared treatment with finasteride and dutasteride in 1630 men over the age of 50 and concluded that after one year of treatment, both groups had statistically

• Drug resistance development often involves structurally

  2024-02-20

  

  Drug resistance development often involves structurally un-related drugs and, specifically both conventional and targeted agents. IGROV-1/Pt1 Cyclosporin D are characterized by resistance to cisplatin and reduced sensitivity to inhibitors of EGF-R and MEK, the up-stream activator of ERK1/2, associa

• br Conclusion In summary screening a small compound library

  2024-02-20

  

  Conclusion In summary, screening a small compound library based on the 3-aminopyridin-2-one motif in a target-blind manner against a 26-kinase panel, representative of the kinome, identified hits that possess good activity and excellent ligand efficiency against MPS1, Aurora A and Aurora B. The b

15843 records 152/1057 page Previous Next First page 上5页 151152153154155 下5页 Last page